CEO, Gen9, US

BIO

Kevin has a passion for synthetic biology and is an active proponent of bringing innovative technologies to market that will enable the next generation of breakthroughs in this exciting field.  Kevin is the President and CEO of Gen9 and currently serves on the board of directors for OH2 Laboratories, Innovate America and Mass Innovation Labs.  He is an advisor to Eve Biomedical, eGenesis and several synthetic biology start-up companies in the greater Boston area.  Prior to Gen9, Kevin was Leader and General Manager of the Next Generation qPCR business at Life Technologies. He also served as Vice President and General Manager of BioTrove, Inc, which was acquired by Life Technologies in 2009, and as Senior Manager at Millennium Pharmaceuticals. Prior to that, Kevin spent 10 years in various scientific and leadership positions in both life science tools and therapeutic development.  He holds an A.B. with honors from Bowdoin College in Biochemistry and Molecular Biology and an MBA in Entrepreneurship, Magna Cum Laude, from Babson College.

MORE INFO

Kevin Munnelly's LinkedIn page
 

Speaker at
28-29 JANUARY 2016, GHENT, BELGIUM
VIB FSVM Research Building UGent, 16-17 September 2013